<code id='DD9F5EB9F5'></code><style id='DD9F5EB9F5'></style>
    • <acronym id='DD9F5EB9F5'></acronym>
      <center id='DD9F5EB9F5'><center id='DD9F5EB9F5'><tfoot id='DD9F5EB9F5'></tfoot></center><abbr id='DD9F5EB9F5'><dir id='DD9F5EB9F5'><tfoot id='DD9F5EB9F5'></tfoot><noframes id='DD9F5EB9F5'>

    • <optgroup id='DD9F5EB9F5'><strike id='DD9F5EB9F5'><sup id='DD9F5EB9F5'></sup></strike><code id='DD9F5EB9F5'></code></optgroup>
        1. <b id='DD9F5EB9F5'><label id='DD9F5EB9F5'><select id='DD9F5EB9F5'><dt id='DD9F5EB9F5'><span id='DD9F5EB9F5'></span></dt></select></label></b><u id='DD9F5EB9F5'></u>
          <i id='DD9F5EB9F5'><strike id='DD9F5EB9F5'><tt id='DD9F5EB9F5'><pre id='DD9F5EB9F5'></pre></tt></strike></i>

          explore

          explore

          author:leisure time    Page View:67913
          3D DNA on a sheet of paper listing nucleic acid sequences — coverage from STAT
          Adobe

          Ultima Genomics, an upstart some observers have called a “dark horse” in the world of DNA sequencing, will soon launch a line of high-power instruments that can read a human genome for as little as $100, the company’s leadership told STAT.

          The sequencer, dubbed the UG 100, is a $1.5 million machine that can read up to 20,000 human genomes a year. The reagents required to operate the instrument cost as little as $1 per billion sequenced DNA bases; that translates to $100 per genome assuming each base in the 3-gigabase human genome is read 33 times, a common industry standard. The company plans to officially launch the product at this year’s Advances in Genome Biology and Technology meeting, which kicks off in Orlando, Fla., on Feb. 5.

          advertisement

          The product’s cost and maximum output put it roughly in the same range as a line of high-throughput instruments launched in September 2022 by Illumina, which controls an estimated 80% of the sequencing market. But Ultima is hoping it can chip into the sequencing giant’s market share among genome centers, large clinical labs, and others with an appetite for reams of genetic data by offering lower operating costs and greater flexibility.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more
          Bill would allow buprenorphine prescription for addiction via telehealth
          Bill would allow buprenorphine prescription for addiction via telehealth

          AdobeAbipartisangroupofsenatorsthisweekintroducedabillthatwouldpermanentlyallowhealthproviderstopres

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          A new drug could help frostbite victims avoid its ravages

          JonCherry/GettyImagesTwodaysafterhisrighthandfroze,HartBeznerrealizedforthefirsttimethathemightlosei